Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency

Next Previous
Trial Profile

A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2636771 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 07 Jun 2022 Results from a cohort of patients with metastatic castration-resistant prostate cancer and PTEN loss presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 21 Sep 2021 Results of an analysis assessing the safely, tolerability and clinical activity of pembrolizumab in combination with GSK2636771 will be in patients with PTEN loss presented at the 46th European Society for Medical Oncology Congress
    • 19 Nov 2017 According to The Institute of Cancer Research media release, results from this trial have been published in Clinical Cancer Research.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top